Your browser doesn't support javascript.
loading
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.
Taavitsainen, S; Engedal, N; Cao, S; Handle, F; Erickson, A; Prekovic, S; Wetterskog, D; Tolonen, T; Vuorinen, E M; Kiviaho, A; Nätkin, R; Häkkinen, T; Devlies, W; Henttinen, S; Kaarijärvi, R; Lahnalampi, M; Kaljunen, H; Nowakowska, K; Syvälä, H; Bläuer, M; Cremaschi, P; Claessens, F; Visakorpi, T; Tammela, T L J; Murtola, T; Granberg, K J; Lamb, A D; Ketola, K; Mills, I G; Attard, G; Wang, W; Nykter, M; Urbanucci, A.
Afiliação
  • Taavitsainen S; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Engedal N; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Cao S; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Handle F; Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Erickson A; Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Prekovic S; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Wetterskog D; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Tolonen T; University College London Cancer Institute, London, UK.
  • Vuorinen EM; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Kiviaho A; Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
  • Nätkin R; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Häkkinen T; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Devlies W; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Henttinen S; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Kaarijärvi R; Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Lahnalampi M; Department of Urology, UZ Leuven, Leuven, Belgium.
  • Kaljunen H; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Nowakowska K; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Syvälä H; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Bläuer M; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Cremaschi P; University College London Cancer Institute, London, UK.
  • Claessens F; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Visakorpi T; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Tammela TLJ; University College London Cancer Institute, London, UK.
  • Murtola T; Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Granberg KJ; Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Lamb AD; Fimlab Laboratories, Ltd, Tampere University Hospital, Tampere, Finland.
  • Ketola K; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Mills IG; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Attard G; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
  • Wang W; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Nykter M; Department of Urology, Churchill Hospital Cancer Centre, Oxford, UK.
  • Urbanucci A; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Nat Commun ; 12(1): 5307, 2021 09 06.
Article em En | MEDLINE | ID: mdl-34489465
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / DNA de Neoplasias / Cromatina / Resistencia a Medicamentos Antineoplásicos / Transcriptoma / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / DNA de Neoplasias / Cromatina / Resistencia a Medicamentos Antineoplásicos / Transcriptoma / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article